CINECA IRIS Institutional Research Information System

SIMIELE, MARCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 7.982
EU - Europa 4.586
AS - Asia 1.567
AF - Africa 65
SA - Sud America 55
OC - Oceania 31
Continente sconosciuto - Info sul continente non disponibili 13
Totale 14.299
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.918
DK - Danimarca 1.391
IT - Italia 760
CN - Cina 739
IE - Irlanda 388
DE - Germania 381
SG - Singapore 379
FR - Francia 352
SE - Svezia 318
FI - Finlandia 236
UA - Ucraina 181
GB - Regno Unito 132
KR - Corea 131
AT - Austria 119
PL - Polonia 109
VN - Vietnam 73
IN - India 72
NL - Olanda 59
CA - Canada 48
ID - Indonesia 47
JP - Giappone 46
BE - Belgio 40
BR - Brasile 31
AU - Australia 29
ZA - Sudafrica 28
ES - Italia 23
TH - Thailandia 17
CZ - Repubblica Ceca 16
RU - Federazione Russa 16
TW - Taiwan 15
EG - Egitto 14
RO - Romania 12
CH - Svizzera 11
EU - Europa 11
MX - Messico 11
GR - Grecia 9
CO - Colombia 8
TR - Turchia 8
HK - Hong Kong 7
HU - Ungheria 7
HR - Croazia 6
PK - Pakistan 6
SA - Arabia Saudita 6
CL - Cile 5
PE - Perù 5
PH - Filippine 5
SN - Senegal 5
NO - Norvegia 4
UZ - Uzbekistan 4
AR - Argentina 3
BZ - Belize 3
IL - Israele 3
PT - Portogallo 3
RS - Serbia 3
SK - Slovacchia (Repubblica Slovacca) 3
TZ - Tanzania 3
AE - Emirati Arabi Uniti 2
AP - ???statistics.table.value.countryCode.AP??? 2
ET - Etiopia 2
GH - Ghana 2
IR - Iran 2
KE - Kenya 2
MA - Marocco 2
MY - Malesia 2
NZ - Nuova Zelanda 2
PY - Paraguay 2
BD - Bangladesh 1
BG - Bulgaria 1
BO - Bolivia 1
CR - Costa Rica 1
EE - Estonia 1
HN - Honduras 1
IQ - Iraq 1
KZ - Kazakistan 1
LI - Liechtenstein 1
LT - Lituania 1
MD - Moldavia 1
ME - Montenegro 1
MT - Malta 1
MU - Mauritius 1
MW - Malawi 1
NA - Namibia 1
NG - Nigeria 1
SC - Seychelles 1
TN - Tunisia 1
UG - Uganda 1
Totale 14.299
Salva come PNG Salva come JPEG
Città #
Ann Arbor 2.688
Chandler 656
Beijing 498
Dublin 386
Fairfield 333
Singapore 308
Torino 300
Ashburn 278
Houston 269
Wilmington 239
Villeurbanne 228
Dearborn 200
Woodbridge 195
Santa Clara 172
Seattle 160
Nyköping 148
Princeton 143
Jacksonville 132
Medford 129
Redwood City 110
Vienna 109
Cambridge 107
Warsaw 103
Columbus 92
Pisa 63
Fremont 60
Milan 51
New York 48
Boston 44
Jakarta 44
Guangzhou 36
Boardman 34
San Diego 30
Turin 30
Munich 28
Dong Ket 26
Nanjing 26
Shanghai 24
Toronto 24
Brussels 23
Paris 21
Hefei 20
Verona 20
Helsinki 18
Norwalk 17
Omaha 15
Rome 13
Amsterdam 12
Kunming 12
Los Angeles 12
Nürnberg 12
Dallas 11
Falls Church 11
Phoenix 11
Taipei 11
Brno 10
Jinan 10
Minneapolis 10
Zhengzhou 10
Silver Spring 9
Washington 9
Cairo 8
Cape Town 8
Des Moines 8
Edinburgh 8
Raritan 8
Buffalo 7
Chengdu 7
Genoa 7
Hangzhou 7
Mountain View 7
Tokyo 7
Brescia 6
Budapest 6
Göteborg 6
Mumbai 6
Nanchang 6
Nola 6
Rio de Janeiro 6
San Mateo 6
Bangkok 5
Chennai 5
Coimbatore 5
Durban 5
Düsseldorf 5
Kharkiv 5
London 5
Louvain 5
Medellín 5
Melbourne 5
Moscow 5
Ottawa 5
Piemonte 5
Rotterdam 5
San Jose 5
Santa Cruz 5
Stockholm 5
Sydney 5
Xian 5
Apo 4
Totale 9.077
Salva come PNG Salva come JPEG
Nome #
UPLC-MS/MS method for quantification of the azathioprine metabolites 6-mercaptoguanosine and 6-methylmercaptopurine riboside in peripheral blood mononuclear cells. 406
Cerebrospinal Fluid Inhibitory Quotients of Antiretroviral Drugs in HIV-positive Patients are Associated with Compartmental Viral Control. 377
Elvitegravir/Cobicistat/Tenofovir/Emtricitabine Penetration in the Cerebrospinal Fluid of Three HIV-Positive Patients 350
High interpatient variability of raltegravir CSF concentrations in HIV-positive patients: a pharmacogenetic analysis. 326
Intracellular accumulation of atazanavir/ritonavir according to plasma concentrations and OATP1B1, ABCB1 and PXR genetic polymorphisms. 311
Inosine triphosphatase polymorphisms and ribavirin pharmacokinetics as determinants of ribavirin-associate anemia in patients receiving standard anti-HCV treatment. 284
Tenofovir clearance is reduced in hiv-positive patients with subclinical tubular impairment 278
HPLC-MS method for the simultaneous quantification of the antileukemia drugs imatinib, dasatinib and nilotinib in human peripheral blood mononuclear cell (PBMC). 277
Raltegravir penetration in seminal plasma of healthy volunteers. 256
Evaluation of the mean corpuscular volume of peripheral blood mononuclear cells of HIV patients by a coulter counter to determine intracellular drug concentrations. 254
Intracellular accumulation of ritonavir combined with different protease inhibitors and correlations between concentrations in plasma and peripheral blood mononuclear cells. 242
Are intracellular drug concentrations underestimated? The role of medium corpuscular volume (MCV) for a correct determination 234
Single-nucleotide polymorphisms ABCB1 3435C>T, 1236C>T and CYP2B6 516G>T influence plasma concentrations of Efavirenz (EFV). 232
Ultra Performance Liquid Chromatography PDA Method for Determination of Tigecycline in Human Plasma. 225
SLC28A2 65C>T predict Sustained Virological Response in patients with hepatitis C treated with interferon and ribavirin, considering all HCV genotype and genotype 1/4. 199
Single-Nucleotide Polymorphisms of ABCB1 Gene Influence Intracellular Concentrations of Dasatinib. 181
Development of Standard Operating Protocols for the Optimization of Cannabis-Based Formulations for Medical Purposes 181
F-33 Early ribavirin plasma concentration and ITPA polymorphisms as determinants of anemia after one month of anti-HCV therapy 180
Could ritonavir intracellular concentrations have a role as active drugs when used as a booster PIs? 179
An HPLC-PDA Method for the Simultaneous Quantification of the HIV Integrase Inhibitor Raltegravir, the New Nonnucleoside Reverse Transcriptase Inhibitor Etravirine, and 11 Other Antiretroviral Agents in the Plasma of HIV-Infected Patients 178
SLC29A1 −706G>C predict haemoglobin decrease in patients with hepatitis C treated with interferon and ribavirin 176
TENOFOVIR AND EMTRICITABINE CSF-TO-PLASMA RATIOS CORRELATE TO THE EXTENT OF BLOOD BRAIN-BARRIER DAMAGE 170
Clinical pharmacology of tenofovir clearance: a pharmacokinetic/pharmacogenetic study on plasma and urines 170
Plasma and Intracellular Imatinib Concentrations in Patients With Chronic Myeloid Leukemia 168
Farmacocinetica dell’anidulafungina in pazienti con fibrosi cistica, trapianto epatico e emodiafiltrazione: dati preliminari. 165
A filter-based cross-sectional analysis of an HIV-positive, HAART-treated cohort in rural Burundi: pharmacokinetics, pharmacogenetics and viral load 164
INTRACELLULAR ACCUMULATION OF RITONAVIR ASSOCIATED WITH DIFFERENT BOOSTED PIS 162
Development and validation of a useful UPLC-MS/MS method for quantification of total and phosphorylated-ribavirin in peripheral blood mononuclear cells of HCV+ patients 161
A HPLC-MS method for the simultaneous quantification of fourteen antiretroviral agents in peripheral blood mononuclear cell of HIV infected patients optimized using medium corpuscular volume evaluation. 160
Development and validation of a new method to simultaneously quantify triazoles in plasma spotted on dry sample spot devices and analysed by HPLC-MS. 160
Tenofovir and emtricitabine cerebrospinal fluid-to-plasma ratios correlate to the extent of blood-brainbarrier damage. 160
Development and validation of an ultra performance liquid chromatography tandem mass method for sildenafil and N-desmethyl sildenafil plasma determination and quantification 159
Determinants of darunavir cerebrospinal fluid concentrations: impact of once-daily dosing and pharmacogenetics. 158
TCH-042 Stability Study of Ganciclovir in 0.9% Sodium Chloride in Different Types of Containers: Optimization of Resources 158
Pharmacokinetics of 400 mg of raltegravir once daily in combination with atazanavir/ritonavir plus two nucleoside/nucleotide reverse transcriptase inhibitors. 157
Determinants of Tenofovir Plasma Trough Concentrations: a Cross-sectional Analysis in the Clinical Setting 157
Ribavirin pharmacokinetics and interleukin 28B plus cytochrome P450 27B1 single-nucleotide polymorphisms as predictors of response to pegylated interferon/ribavirin treatment in patients infected with hepatitis C virus genotype 1/4. 156
A validated high-performance liquid chromatography-ultraviolet method for quantification of the CCR5 inhibitor maraviroc in plasma of HIV-infected patients. 156
Cannabis FM2: optimization and standardization of galenic preparations. 153
Undetectable Ritonavir Plasma Concentrations in Different Boosted PI-based Regimens as a Marker of Non-Adherence: analysis of a large TDM Registry 152
Influenza dei polimorfismi C3453T, C1236T, G2677T/A del gene MDR1 sulle concentrazioni plasmatiche di daptomicina 152
Tenofovir Plasma Concentrations According to Companion Drugs: a Cross-sectional Study in HIV-positive Patients with Normal Renal Function. 151
Sequential therapy with entecavir and PEG-INF in patients affected by chronic hepatitis B and high levels of HBV-DNA with non-D genotypes. 151
Single-nucleotide polymorphism PXR 7635G>A influences plasma concentrations of Efavirenz in CYP2B6 516G>T carriers 151
Pharmacokinetics of switching unboosted atazanavir coadministered with tenofovir disoproxil fumarate from 400 mg once daily to 200 mg twice daily in HIV-positive patients. 151
Pharmacokinetics of Raltegravir, Etravirine and Maraviroc regimen in the clinical setting 150
MONITORING OF VIROLOGICAL AND PHARMACOLOGICAL CEREBROSPINAL FLUID PARAMETERS IN HAART-TREATED HIV-POSITIVE PATIENTS IN THE CLINICAL SETTING 149
Development, validation, and routine application of a high-performance liquid chromatography method coupled with a single mass detector for quantification of itraconazole, voriconazole, and posaconazole in human plasma. 147
Pharmacokinetics of the Dual NRTI- and Protease Inhibitor-sparing Regimen Raltegravir plus Nevirapine in HIV-1+ Patients 145
A UPLC-MS/MS method for the simultaneous plasma quantification of all isomeric forms of the new anti-HCV protease inhibitors boceprevir and telaprevir. 145
Development and validation of an UPLC-PDA method to quantify daptomycin in human plasma and in dried plasma spots. 144
Farmacocinetica della caspofungina in pazienti sottoposti a trapianto epatico. 143
Intracellular accumulation of the new integrase inhibitors elvitegravir and dolutegravir in HIV patients 143
Sviluppo di protocolli operativi standard per l’ottimizzazione di preparazioni galeniche allestite con cannabis “FM2” 143
Steady-state Raltegravir Penetration in Seminal Plasma of Healthy Volunteers 141
SLCO3A1 expression is a major determinant of atazanavir PBMC penetration in HIV infected patients 141
High Interpatient Variability of Raltegravir Cerebrospinal Fluid Concentrations in HIV-positive Patients: a Pharmacogenetic Analysis 141
Seminal pharmacokinetics and antiviral efficacy of once-daily maraviroc plus lopinavir/ritonavir in HIV-infected patients. 141
Prophylaxis drug monitoring of itraconazole and voriconazole in the paediatric onco-haematological setting 138
How effective are the use of DBS and DPS as tools to encourage widespread therapeutic drug monitoring? 137
Prophylactic drug monitoring of itraconazole in an oncohematological pediatric patient population. 134
Intracellular Pharmacokinetics of Boosted and Unboosted Atazanavir in HIV Infected Patients 133
Correlation between Thiopurine S-Methyltransferase Genotype and Adverse Events in Inflammatory Bowel Disease Patients 131
Cannabinoids concentration variability in cannabis olive oil galenic preparations 122
A UHPLC-MS/MS method for the quantification of direct antiviral agents simeprevir, daclatasvir, ledipasvir, sofosbuvir/GS-331007, dasabuvir, ombitasvir and paritaprevir, together with ritonavir, in human plasma 112
A description of Cannabinoid levels in Cannabis oil by high-performance liquid chromatography-mass spectrometry in a reference laboratory of North-Italy 105
Development and validation of an UPLC MS-MS method for the quantification of new direct antiretroviral agents simeprevir, daclatasvir sofosbuvir and its metabolite GS-332007 in human plasma 101
ABCB1 3435C>T e CYP2B6 516G>T possono predire le concentrazioni plasmatiche ottimali di Nevirapina 99
Dried Plasma/Blood Spots for Monitoring Antiretroviral Treatment Efficacy and Pharmacokinetics: a Cross-sectional Study in Rural Burundi. 97
UPLC-MS/MS method for the simultaneous quantification of anti-HBV nucleos(t)ides analogs: Entecavir, lamivudine, telbivudine and tenofovir in plasma of HBV infected patients 93
Development and validation of a new UPLC-PDA method to quantify linezolid in plasma and in dried plasma spots 88
High four weeks’ entecavir plasma concentration is a negative predictor of HBV DNA drop after three months of therapy 87
Efavirenz pharmacogenetics in a cohort of Italian patients 87
Cannabis-Based Oral Formulations for Medical Purposes: Preparation, Quality and Stability 87
UPLC–MS/MS method for the simultaneous quantification of three new antiretroviral drugs, dolutegravir, elvitegravir and rilpivirine, and other thirteen antiretroviral agents plus cobicistat and ritonavir boosters in human plasma 86
Single-nucleotide polymorphisms ABCB1 3435C>T, 1236C>T and CYP2B6 516G>T predict higher plasma concentrations of nevirapine (NVP). 85
Negative Predictive Value of IL28B, SLC28A2, and CYP27B1 SNPs and Low RBV Plasma Exposure for Therapeutic Response to PEG/IFN-RBV Treatment. 85
New UPLC-MS/MS method for simultaneous determination of dolutegravir, elvitegravir, rilpivirine and other 14 HIV drugs in human plasma 81
A UHPLC-MS/MS method for the quantification of currently used direct antiviral agents in human plasma and evaluation of "normalized matrix effect" 81
Development and validation of a useful HPLC-UV method for quantification of total and phosphorylated-ribavirin in blood and erythrocytes of HCV+ patients 80
Development and validation of a simultaneous extraction procedure for HPLC-MS quantification of daptomycin, amikacin, gentamicin, and rifampicin in human plasma. 77
HPLC-MS method for the quantification of nine anti-HIV drugs from dry plasma spot on glass filter and their long term stability in different conditions. 75
Class-specific relative genetic contribution for key antiretroviral drugs 75
Cerebrospinal Fluid Concentrations Above Drugs IC95s are Associated With CSF Viral Loads Below 50 copies/ml 74
Atazanavir intracellular concentrations remain stable during pregnancy in HIV-infected patients 73
Rilpivirine Pharmacokinetics in 3 HIV-Positive Patients With Liver Cirrhosis Concomitantly Receiving Pantoprazole 71
New HPLC-MS method for the simultaneous quantification of the antileukemia drugs imatinib, dasatinib, and nilotinib in human plasma 70
A LC-MS method to quantify tenofovir urinary concentrations in treated patients 68
Pharmacokinetics of maraviroc administered at 150 mg QD in association with lopinavir/ritonavir as a part of a novel NRTI-sparing regimen in naïve patiens 67
A validated HPLC-MS method for quantification of the CCR5 inhibitor maraviroc in HIV+ human plasma 65
PXR 63396C>T is a predictor of boosted and unboosted atazanavir plasma concentrations 64
Single nucleotide polymorphisms of ABCB1 gene influence on intracellular concentrations of dasatinib. 64
Pharmacokinetics of an antiretroviral regimen in a patient unable to swallow solid oral dosage forms 62
Determinants of Renal Tubular Dysfunction in HIV-positive Patients of More than 50 Years-old 61
Impact of Different Procedures of Galenic Formulations of Cannabis on Cannabinoids Contents 58
Voriconazole and atazanavir: a CYP2C19-dependent manageable drug-drug interaction. 57
Therapeutic Drug Monitoring of Boosted Protease Inhibitors and 48-week Risk of Virological Failure 56
Intrapatient and interpatient pharmacokinetic variability of raltegravir in the clinical setting. 55
QUALITATIVE AND QUANTITATIVE EVALUATION OF DIFFERENT PHARMACEUTICAL PRODUCTS CONTAINING QUETIAPINE: BRAND VERSUS GENERIC 52
Single Nucleotide Polymorphisms of ABCB1 Gene Influence Daptomycin Pharmacokinetics in Adult Patients. [A-1769] 51
Totale 14.545
Salva come PNG Salva come JPEG
Categoria #
all - tutte 35.949
article - articoli 0
book - libri 0
conference - conferenze 13.277
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 49.226
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20202.589 0 0 0 0 374 569 257 133 132 281 363 480
2020/20211.515 354 51 42 86 88 77 76 49 105 123 105 359
2021/20223.317 324 298 318 346 249 277 355 285 205 98 287 275
2022/20231.990 208 111 43 184 202 529 133 144 209 38 127 62
2023/2024817 77 140 45 50 65 136 26 60 5 31 70 112
2024/2025840 16 98 109 180 437 0 0 0 0 0 0 0
Totale 15.034